The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety of mitazalimab in combination with mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): An interim analysis of the optimize-1 phase 1b/2 study.
 
Hans Prenen
Honoraria - Amgen; AstraZeneca; Bayer; Roche; Sanofi
Consulting or Advisory Role - Biocartis; cureteq
 
Ivan Borbath
Honoraria - Bayer (Inst); Roche/Genentech (Inst); Taiho Pharmaceutical (Inst)
Consulting or Advisory Role - Lilly (Inst)
Research Funding - SERVIER (Inst)
Travel, Accommodations, Expenses - Ipsen (Inst)
 
Karen Paula Geboes
Consulting or Advisory Role - BMS (Inst); Ipsen (Inst); SERVIER (Inst)
Speakers' Bureau - BMS (Inst); Ipsen (Inst)
Expert Testimony - servier (Inst)
Travel, Accommodations, Expenses - servier (Inst)
 
Philippe Alexandre Cassier
Honoraria - Amgen
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb/Celgene; Janssen Oncology; OSE Immunotherapeutics
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); GlaxoSmithKline (Inst); Innate Pharma (Inst); Janssen (Inst); Lilly (Inst); Loxo (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Plexxikon (Inst); Roche/Genentech (Inst); Taiho Pharmaceutical (Inst); Toray Industries (Inst); Transgene (Inst)
Travel, Accommodations, Expenses - Novartis; OSE Immunotherapeutics; Roche
 
Aurélien Lambert
Consulting or Advisory Role - Advanced Accelerator Applications; AstraZeneca/MedImmune; Bayer; GlaxoSmithKline; Ipsen; Janssen; Merck KGaA; Merck Serono; Novartis; Pierre Fabre; Servier/Pfizer
Travel, Accommodations, Expenses - Merck KGaA; Pfizer
 
Emmanuel Mitry
Honoraria - AstraZeneca/Daiichi Sankyo; Esteve; Pierre Fabre; SERVIER; SERVIER
 
Teresa Macarulla
Consulting or Advisory Role - Ability Pharma; Advance Medical; Amgen; Aptitude Health; AstraZeneca; Basilea; Baxter; BioLineRX; Celgene; Eisai; Ellipses Pharma; Esteve; Incyte; Ipsen; Janssen; Lilly; Medscape; MFAR, Marketing Farmacéutico & Investigación Clínica; MSD; Novocure; Paraxel; Prime Oncology; QED Therapeutics; Roche; Sanofi/Aventis; SERVIER; Zymeworks
Research Funding - Abbvie (Inst); Ability Pharma (Inst); Agios (Inst); Amc Medical Research (Inst); Amgen (Inst); Armo Biosciences (Inst); ASLAN Pharmaceuticals (Inst); ASTRAZENECA (Inst); Basilea Pharmaceutical (Inst); Bayer (Inst); Beigene (Inst); BiolineRx (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (BMS) (Inst); Cantargia AB (Inst); Celgene (Inst); Eisai (Inst); ERYTECH Pharma (Inst); Fibrogen (Inst); Genentech (Inst); Halozyme (Inst); Immunomedics (Inst); Incyte (Inst); Ipsen (Inst); Keralty Group (Inst); Lilly (Inst); Loxo (Inst); Medimmune (Inst); Merck Sharp & Dohme (Inst); Merrimack (Inst); Millennium (Inst); Nelum Corp. (Inst); Novartis (Inst); Novocure (Inst); OncoMed (Inst); Pfizer (Inst); Pharmacyclics (Inst); Roche (Inst); Roche (Inst); VCN Biosciences (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Celgene; H3 Biomedicine; Incyte; Merck; Prime Oncology; Sanofi; SERVIER
 
Julien Taieb
Consulting or Advisory Role - Amgen; AstraZeneca; BMS; Merck KGaA; MSD; Novartis; Pierre Fabre; Roche; SERVIER
Speakers' Bureau - Amgen; Merck; MSD; Pierre Fabre; SERVIER
 
Jean-Frédéric Blanc
Honoraria - AstraZeneca; Bayer Schering Pharma; Eisai; INCYTE; IPSEN; Roche; SERVIER
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; IPSEN; ROCHE; SERVIER
Travel, Accommodations, Expenses - Bayer Schering Pharma
 
Jaime Feliu Batlle
Consulting or Advisory Role - Amgen; Eisai; ipsen; Merck Serono; Novartis; Roche/Genentech
Research Funding - Merck Serono
Travel, Accommodations, Expenses - Amgen
 
Mercedes Rodríguez Garrote
Honoraria - Merck
 
Roberto A. Pazo Cid
Consulting or Advisory Role - Bristol-Myers Squibb/Celgene; Eisai Europe; Roche
Speakers' Bureau - AstraZeneca Spain; BMS GmbH & Co. KG; SERVIER
Travel, Accommodations, Expenses - BMS GmbH & Co. KG; Lilly
 
Manuel Valladares-Ayerbes
Honoraria - Amgen; Merck; Sanofi
Consulting or Advisory Role - Amgen; Bayer; Merck; SERVIER
Speakers' Bureau - Amgen; Bayer; Celgene; Merck; Roche; SERVIER
Research Funding - Amgen; Roche
Travel, Accommodations, Expenses - Amgen; Merck; Roche; SERVIER
 
Karin Nordbladh
Employment - Alligator Bioscience
Stock and Other Ownership Interests - Alligator Bioscience; Johnson & Johnson
 
Karin Enell Smith
Employment - Alligator Bioscience
Stock and Other Ownership Interests - Alligator Bioscience
Patents, Royalties, Other Intellectual Property - Inventor "Novel Combination Therapies and Uses Thereof" Inventor "Anti-Cd40 Human Antibodies" Inventor "Novel Anti-Cd137 Antibodies and Uses Thereof"
 
Peter Ellmark
Employment - Alligator Bioscience
Leadership - Alligator Bioscience
Stock and Other Ownership Interests - Alligator Bioscience
Patents, Royalties, Other Intellectual Property - Inventor on patents assigned to Alligator Bioscience
 
Malin Carlsson
Employment - Alligator Bioscience; Triomed AB (I)
Leadership - Alligator Bioscience
Stock and Other Ownership Interests - Alligator Bioscience
 
Yago Pico de Coaña
Employment - Alligator Bioscience
Stock and Other Ownership Interests - Alligator Bioscience
 
Sumeet Vijay Ambarkhane
Employment - Alligator Bioscience; MorphoSys
Leadership - Alligator Bioscience
Stock and Other Ownership Interests - Alligator Bioscience; MorphoSys
Patents, Royalties, Other Intellectual Property - Patent under review
Travel, Accommodations, Expenses - Alligator Bioscience; MorphoSys
 
Jean-Luc Van Laethem
No Relationships to Disclose